methods

Study Oversight
This study was approved by the institutional review board of Beijing Tiantan Hospital of Capital Medical University (Beijing, China). The index patient provided written informed consent.
Immunohistochemistry
Routine H & E staining was performed on formalinfixed tissue specimens to confirm histopathological diagnosis. Immunohistochemical staining was performed using the Bond automatic stainer and Bond ready-touse antisynaptophysin antibody (both from Leica). Images were obtained at 200× magnification using a Nikon Eclipse Ci microscope with a Nikon DS-Fi2 camera.
DNA Extraction
DNA was extracted from formalin-fixed, paraffin-embedded tumor tissues using the QIAamp DNA FFPE Tissue Kit (Qiagen).
Polymerase Chain Reaction Conditions
Standard polymerase chain reaction (PCR) experiments contained 200-500 ng genomic DNA, 25 ml Taq 2× Master Mix (New England BioLabs), and 0.25 ml each of forward and reverse primers (100 mM) in a final volume of 50 ml. The PCR conditions were as follows: denaturation at 94°C for 15 minutes; followed by 40 cycles of 94°C for 30 seconds (denaturation), 55°C for 30 seconds (primer annealing), and 68°C for 60 seconds (extension), with a final extension step at 68°C for 5 minutes.
Peptide Nucleic Acid Design and PCR Conditions
The peptide nucleic acid (PNA) designed to detect wildtype IDH1 was produced by PNA Bio. The sequence of the PNA was CATCATAGGTCGTCATGCTT-Lys-Lys. The 2 terminal lysine residues were added for improved solubility. The PCR experiments contained 200-500 ng genomic DNA, 25 ml Taq 2× Master Mix (New England BioLabs), 0.25 ml each of forward and reverse primers (100 mM), and 0.5 ml PNA (100 nM) in a final volume of 50 ml. The PCR conditions were as follows: denaturation at 94°C for 15 minutes; followed by 40 cycles of 94°C for 30 seconds (denaturation), 68°C for 60 seconds (PNA hybridization), 55°C for 30 seconds (primer annealing), and 72°C for 60 seconds (extension), with a final extension step at 72°C for 7 minutes.
Detection of R132 Mutation With Nested PCR and PNA Application PCR amplification to introduce a site-directed mutation was initially performed, using 100 nM PNA as described above (forward primer ACCAACGACCAAGTCACCAA, reverse primer GTGTTGAGATGGACGCCTATT). PCR products were purified using QIAquick PCR columns (Qiagen). Subsequently, PCR amplification was repeated with the PNA, using nested primers (forward primer TGTGGAAATCACCAAATGGCAC, reverse primer TT GCTTAATGGGTGTAGATACCA). After purification, PCR products were analyzed by gel electrophoresis and subjected to Sanger sequencing for IDH1 mutations, using the nested forward primer. The GenBank (National Center for Biotechnology Information) accession number for IDH1 is NM_005896.2.
case report
History and Examination
A 28-year-old man presented with a 3-year history of voice hoarseness and dysphagia, and a 6-month history of left-sided blurred vision. His medical history was significant for development of multiple palpable nodular masses of the left hand beginning at 7 years of age (Fig. 1A) , later accompanied by formation of subcutaneous blue, soft, nontender masses, diagnosed as hemangiomas on physical examination (Fig. 1A, inset) . Radiographs of the left hand showed skeletal phalangeal malformation with calcific nodules and multiple enchondromas (Fig. 1B) . Chest CT demonstrated enchondromas of the bilateral ribs and scapulae (Fig. 1C) . Technetium-99m methylene diphosphonate whole-body bone scintigraphy revealed foci of intense tracer uptake, involving the right humerus, right ulna, right femur, right fibula, right tibia, left humerus, left radius, left hand, left femur, left fibula, and left tibia (Fig.  1D ). Based on these findings, the patient was diagnosed with Maffucci syndrome.
Neurological examination revealed left-sided deficits in hearing and gag reflex, bilateral temporal hemianopia, and decreased visual acuity (left eye 20/30; right eye 20/50). Brain MRI demonstrated 2 heterogeneously enhancing lesions, 1 in the left jugular foramen ( Fig. 2A and B) and the other in the suprasellar region ( Fig. 2C and D). The latter was suggestive of a pituitary macroadenoma. Serum prolactin (PRL), insulin-like growth factor-I, growth hormone (GH), cortisol, adrenocorticotropic hormone (ACTH), thyroid hormone, thyroid-stimulating hormone (TSH), luteinizing hormone (LH), and folliclestimulating hormone (FSH) were normal. A diagnosis of Maffucci syndrome associated with a nonfunctional pituitary adenoma was proposed.
Operation and Postoperative Course
A subtotal resection of the contrast-enhancing left jugular foramen lesion through a retrosigmoid approach was performed, resulting in significant improvement of the patient's dysphagia and auditory acuity. Histopathological review of the surgical specimen diagnosed a chondrosarcoma. Ten months after the first operation, the patient underwent gross-total resection of the suprasellar lesion via a subfrontal approach, revealing a diagnosis of pituitary adenoma. His postoperative recovery was uneventful other than transient polyuria. At the 2-year follow-up, the patient's voice hoarseness and visual acuity were significantly improved.
Pathological Examination and DNA Sequencing
Pathological examination of the jugular foramen specimen revealed a Grade II chondrosarcoma, characterized by moderate cellularity with occasional mitotic figures, cellular atypia, and increased muco-myxoid degeneration of chondroid matrix (Fig. 2E) . Histopathological review of the pituitary adenoma demonstrated a highly cellular tumor with prominent monomorphism and loss of the normal reticulin meshwork (Fig. 2F) . Immunohistochemical staining for synaptophysin confirmed this tumor to be of neuroendocrine origin (Fig. 2F, inset) . Additional immunohistochemical investigation was negative for GH, PRL, LH, FSH, TSH, and ACTH (not shown).
Sanger sequencing of DNA from the pituitary adenoma revealed a c.394C > T mutation, a substitution of arginine at codon 132 with cysteine (R132C) (Fig. 3 center) .
To confirm these results, we performed repeat Sanger sequencing on significantly limited, remaining tissue, using nested PCR technique and a custom-designed PNA against the wild-type IDH1 sequence (Fig. 3 lower) . Use of PNA has been demonstrated to be an effective PCR clamp of wild-type sequences in samples where mutated cells are sparse. 6 Similarly, chondrosarcoma tissue was very limited but using the same techniques, a c.394C > T (R132C) mutation was detected (Fig. 3 upper) .
discussion
Although pituitary adenomas in patients with Maffucci syndrome have been previously described, 27 none established causality of pituitary adenoma in Maffucci syndrome through analysis of IDH1/2 mutations. Our report of a pituitary adenoma sharing an identical IDH1 mutation with a chondrosarcoma in a patient with Maffucci syndrome supports the inclusion of pituitary adenomas among tumors characterizing Maffucci syndrome. Further investigations may reveal IDH1/2 mutations in other tumor types reported to arise in patients with Maffucci syndrome.
Excluding the current study, 11 cases of pituitary adenoma in patients with Maffucci syndrome have been described and are shown in Table 1 . 5, 8, 10, 11, 14, 15, 19, 20, 23, 27, 28 Among these, the majority (6/11) presented solely with visual field deficits, as did our patient. Further, none exhibited symptoms or evidence from immunohistochemical staining and/ or laboratory testing of hormonal abnormalities, indicative of a predominance of nonfunctional pituitary adenomas in this patient population. All patients except for 2 underwent resection, 1 of whom was diagnosed postmortem. 5 The other patient was treated with radiation only and was without recurrence at the 3-year follow-up. 19 There were 2 more cases of tumor recurrence within 3 years after surgical removal of the pituitary adenoma. 10, 28 Further, similar to the patient described by Miki et al., 20 there was little evidence of sellar enlargement upon review of imaging from our patient, which, although atypical for a pituitary adenoma, does not exclude its diagnosis. 25 Taken together, the clinical course of our patient is consistent with these previous studies, i.e., he presented solely with visual field deficits secondary to a nonfunctional pituitary adenoma and responded well to surgical treatment alone.
To our knowledge, the current case represents the first case of an IDH1-mutated pituitary adenoma. Balss et al. analyzed 23 samples of sporadic nonfunctional pituitary adenomas and failed to detect IDH1 mutations, using direct DNA-sequencing techniques. 4 Similarly, Ikota et al. performed immunohistochemical staining for IDH1 mutations in 42 pituitary adenoma samples, of which 2 exhibited 10%-30% positive immunoreactivity. 9 However, positive staining in these samples was confined to the cytoplasm. Because of this, the authors stated these find- ings should be considered negative, given the absence of concomitant nuclear staining, which is required for immunohistochemical diagnosis of IDH1 mutations.
Maffucci syndrome was originally theorized as a condition of mesodermal dysplasia. 18 However, our study and Moriya et al. 22 question this theory because pituitary adenomas and astrocytomas arise from neuroectodermal tissues. Our finding of the same IDH1 mutation in the chondrosarcoma (mesodermal origin) and pituitary adenoma (neuroectodermal origin) suggests IDH1/2 mutations are early postzygotic events in Maffucci syndrome, occurring prior to gastrulation. 1, 22 It is unclear which cell types are affected and harbor tumorigenic potential in Maffucci syndrome. Other endocrine tumors have been described in Maffucci syndrome, including thyroid adenoma, parathyroid adenoma, pheochromocytoma, and paraganglioma. 7, 12, 16, 20, 24 Further, endocrine tumor syndromes have been attributed to mutations in cellular metabolism genes, including succinate dehydrogenase (SDH), hypoxia-inducible factor 2-alpha (HIF2A), multiple endocrine neoplasia 1 (MEN1), rearranged during transfection (RET), and Von Hippel-Lindau (VHL). IDH1/2 mutations similarly alter metabolic pathways via mutant enzymatic production of the onco-metabolite, D-2-hydroxyglutarate, promoting development of low-grade gliomas and hematopoietic malignancies. 21 As this report suggests, IDH1/2 mutations in Maffucci syndrome may affect cells beyond mesenchymal lineage, including neuroectodermal cells that may form tumors. IDH1/2 sequencing of more neuroendocrine tumors from patients with Maffucci syndrome will be required to answer this question.
In summary, we provide sufficient genetic evidence for the inclusion of pituitary adenomas among tumors that arise from IDH1 mutation mosaicism in Maffucci syndrome. Because IDH1/2 mutations in Maffucci syndrome predispose cells to, rather than incite, tumorigenesis, it is yet to be seen whether IDH1 and IDH2 represent cancersusceptibility genes, similar to SDH, MEN1, and RET. 
